{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:14:52Z","timestamp":1786990492574,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijcard.2018.03.121","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T20:25:34Z","timestamp":1526415934000},"page":"118-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study"],"prefix":"10.1016","volume":"264","author":[{"given":"Victor","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Streefkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Modgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.03.121_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jcpt.12363","article-title":"Neprilysin inhibition with sacubitril\/valsartan in the treatment of heart failure: mortality bang for your buck","volume":"41","author":"Ansara","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/all.12680","article-title":"Angioedema induced by cardiovascular drugs: new players join old friends","volume":"70","author":"Bas","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"5","key":"10.1016\/j.ijcard.2018.03.121_bb0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0897190014546101","article-title":"Angioedema related to angiotensin inhibitors","volume":"27","author":"Knecht","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0045","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaip.2017.03.017","article-title":"Cardiovascular and diabetic medications that cause Bradykinin-mediated angioedema","volume":"5","author":"Hudey","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0050","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.molimm.2010.05.010","article-title":"The plasma bradykinin-forming pathways and its interrelationships with complement","volume":"47","author":"Kaplan","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1081-1206(10)60151-2","article-title":"Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor","volume":"103","author":"Haymore","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0060","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0196-9781(00)00348-X","article-title":"The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins","volume":"21","author":"Blais","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0162-3109(99)00133-2","article-title":"Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"43","author":"Blais","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0070","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0075","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/0006-2952(86)90727-6","article-title":"Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N","volume":"35","author":"Sheikh","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1398-9995.2007.01427.x","article-title":"Nonallergic angioedema: role of bradykinin","volume":"62","author":"Bas","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0085","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0095","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-3565(24)38947-5","article-title":"Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts","volume":"295","author":"Blais","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0110","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/srep27909","article-title":"Structure of neprilysin in complex with the active metabolite of sacubitril","volume":"6","author":"Schiering","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","article-title":"Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat","volume":"57","author":"Hegde","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2125.1999.00093.x","article-title":"Angioedema due to ACE inhibitors: increased risk in patients of African origin","volume":"48","author":"Gibbs","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0140","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0145","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0150","author":"Center for Drug Evaluation and Research"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0155","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0160","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11906-003-0045-6","article-title":"Recent clinical trials with omapatrilat: new developments","volume":"5","author":"Zanchi","year":"2003","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0165","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.121_bb0170","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.121_bb0175","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/hr.2016.151","article-title":"Long-term (52-week) safety and efficacy of sacubitril\/valsartan in Asian patients with hypertension","volume":"40","author":"Supasyndh","year":"2017","journal-title":"Hypertens. Res."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317378026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317378026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:37:48Z","timestamp":1759091868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317378026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":35,"alternative-id":["S0167527317378026"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.121","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}